Miguel Arcinas is Silverback’s Vice President of Corporate Development and Investor Relations. He has over 14 years of multi-disciplinary experience in biotech corporate strategy, business development, investor relations, and clinical operations. Prior to Silverback, Miguel was a member of the corporate development team at Synthorx from 2018 through its acquisition by Sanofi in 2020 for $2.5B, serving on the company’s M&A team. Prior to Synthorx, he held corporate development and operational roles of increasing responsibility at ACADIA Pharmaceuticals and Ignyta (acquired by Roche for $2.0B in 2017), where he led the execution of the company’s external diagnostic strategy and supported business development initiatives. Miguel began his career in clinical operations, having held roles at AbbVie, Parexel International, and Synteract. He received his MBA from the University of Chicago Booth School of Business and his B.S. in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles.
- Science & Technology
- Investors & Media